3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
1
Leukemia, Plasma Cell
1
Interventions
Dexamethasone
47
Lenalidomide
31
daratumumab
24
Bortezomib
23
pomalidomide
19
carfilzomib
15
Specimen Handling
15
Cyclophosphamide
15
Calcium Dobesilate
15
Biopsy
15
Magnetic Resonance Spectroscopy
11
talquetamab
9
isatuximab
9
Melphalan
9
iberdomide
8
dexamethasone acetate
8
dexamethasone 21-phosphate
8
auricularum
8
fludarabine
7
belantamab mafodotin
7
selinexor
5
X-Rays
5
tocilizumab
4
fludarabine phosphate
4
elotuzumab
4
Nuclear Medicine Department, Hospital
4
trametinib
3
dabrafenib
3
Whole-Body Irradiation
3
Thalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Budesonide
×
Plasma cell
×
30 days
×
Clear all
NCT05405387
2026-06-05
IMPACT
University of Utah
Phase 2
Recruiting
120 enrolled